Diagnosing Dx

In this episode of Diagnosing Dx, I’m joined by Slava Akmaev, Chief AI Officer and COO at BPGbio, and one of the earliest pioneers applying AI to diagnostics and precision medicine. We discuss how AI has evolved from early scepticism in pharma to becoming the operational backbone of modern biotech, how it’s reshaping clinical trial design and diagnostic development, and what it will take to rebuil...

In this episode of Diagnosing Dx, I sit down with Jenna Anderson, CEO of KiHealth, the company behind a breakthrough diagnostic test that can detect Type 1 diabetes years before symptoms appear. We discuss how this innovation could transform preventative healthcare, why consumer empowerment is reshaping the industry, and how KiHealth is building a future where early detection becomes the norm. Tak...

In this episode of Diagnosing Dx, I’m joined by Sally Bowden and BJ Kerns, founders of P3 Consulting, who help early-stage diagnostics startups navigate the realities of funding, regulation, and leadership.   We unpack why so much innovation never makes it off the shelf, what investors expect before backing a product, and how founders can de-risk their science to survive in today’s challenging mar...

In this episode of Diagnosing Dx, I’m joined by Ben Casavant, Co-founder and CEO of Tasso, a company redefining how blood testing works. Ben shares how a PhD side project turned into a diagnostics breakthrough, with over $120 million raised and more than two million patients served. He explains how Tasso’s painless, at-home blood collection device is making healthcare more accessible, and why inno...

In this episode of Diagnosing Dx, I’m joined by Julie Ballard, founder of Carrot Clinical and Tiger Team Bio, who has helped shape leading diagnostics companies including Genomic Health, GRAIL, and Guardant Health. Julie shares her journey from clinical laboratory scientist to entrepreneur and consultant, and what she’s learned from years of helping startups navigate the complex world of lab opera...

This week on Diagnosing Dx, I’m joined by Kaylene Ready, Chief Product Officer at Juniper Genomics, a company transforming the future of IVF through whole genome embryo testing. We explore how Juniper is turning IVF from a 50/50 coin flip into a more certain path to success, empowering families with better information and outcomes. Kayleen also shares how her background in genetics and startup lea...

This week on Diagnosing Dx, I’m joined by Scott O’Brien, who helped lead GenMark from a small startup to a $1.8 billion acquisition by Roche. Scott shares how his transition from science to commercial strategy shaped GenMark’s journey, the critical role of customer experience in competing against industry giants, and what it really takes to scale a diagnostics company through both breakthroughs an...

This week on Diagnosing Dx, I’m joined by Josh Smith, founder of Bench in a Box and scientist with a background in genetics and microbiology. Josh shares the breakthrough idea that inspired his platform, the journey to patent-pending status, and the realities of building a diagnostics startup in today’s economic climate. 🔥 What You’ll Learn: • The breakthrough behind Bench in a Box and its role i...

This week on Diagnosing Dx, I’m joined by Victoria Polyanskaya, a healthcare leader with over 10 years of experience who is driving global expansion for LinusBio.   We explore how diagnostics companies can successfully scale internationally, the opportunities in emerging markets, and the hard truths leaders need to hear when looking abroad.   🔥 What You’ll Learn: • Why exposomics is shaping the n...

This week on Diagnosing Dx , I’m joined by Dean Remy, a 35-year veteran of the life sciences industry, founder, and fundraising strategist. Dean shares his unique journey from diagnostics into technology and commercial leadership, and why fractional leadership is becoming a smart, cost-effective model for today’s startups. We dive into the evolving world of fundraising, the growing gap between inv...

This week on Diagnosing Dx, I’m joined by Rachel Jones,former Chief Commercial Officer at BioFire and now at VedaBio. Rachel shares her remarkable journey from bench scientist to helping rebrand Idaho Technology into BioFire, scaling its commercial team from just 12 people into a billion-dollar diagnostics powerhouse, and ultimately shaping one of the most iconic success stories in infectious dise...

This week on Diagnosing Dx, I’m joined by Bradley Murray, CEO and co-founder of Delve Bio. Bradley shares his journey from academic research, success as a biotech startup, investment into life sciences and onto entrepreneurship, andhow those experiences shaped his approach to building diagnostics that put patients first.   We dive into why execution, not just vision is critical for survival in tod...

This week on Diagnosing Dx, I’m joined by Tara Maddala,statistician, diagnostics veteran, and founder of Pandora Bio and Tiger Team Bio, whose career also spans Genomic Health and Grail.   We explore how the truth-seeking culture at Genomic Healthshaped her approach to building and advising early-stage companies, why mental health diagnostics is still decades behind, and how AI is often misreprese...

This week on Diagnosing Dx, I’m joined by Mark Oldroyd, a commercialisation strategist with over 30 years in healthcare, including leadership roles at Foundation Medicine, Tempus, and C2i Genomics.   Mark has guided diagnostics and omics companies across the US, Europe, and Asia, helping them find the right path from breakthrough science to a sustainable business.   🔥What You’ll Learn: • Why movi...

This week on Diagnosing Dx, I’m joined by James Kelley, Chief Medical Officer at Pictor Labs and a respected leader in lab medicine and diagnostics. We explore how AI is reshaping pathology, what makes virtual staining such a transformative innovation, and why data ownership and transparency are becoming urgent conversations for clinicians. From regulatory frameworks to AI education in healthcare,...

This week on Diagnosing Dx, I’m joined by Vincent Funari, a genomics leader whose career spans from the Human Genome Project to pioneering liquid biopsy assays and driving innovation at NeoGenomics during its major growth years.   We dive into how Vincent scaled R&D through M&A, led testing innovation during the COVID-19 crisis, and earned praise from the FDA for breakthrough assay develop...

On this week’s episode of Diagnosing Dx, I’m joined by Mort Minaee, a seasoned regulatory strategist with over 35 years of experience at companies like Roche, Abbott, and Guardant Health. We unpack the FDA’s recent ruling, and reversal on LDTs (Laboratory Developed Tests) and what this moment of uncertainty means for diagnostics startups. Mort shares how to build a credible regulatory strategy tha...

This week on Diagnosing Dx, I’m joined by Janine McMurdie, Chief Commercial Officer at Pictor, a company unlocking the next wave of innovation in diagnostics through proteomics. With a career spanning industry giants like Amgen and IonTorrent, Janine shares what it takes to lead in a fast-evolving space - where scalability, speed, and strategy matter more than ever. We dive into how Pictor’s flexi...

This week on Diagnosing Dx, I’m joined by Dr. Sam Agus, a neurologist and diagnostics innovator with over 20 years of experience in clinical trials, biomarker development, and early-stage ventures.   In this candid conversation, Sam shares the hard truths about why diagnostics companies struggle for funding, why prognostics are quietly becoming the next frontier, and how early partnerships - espec...

This week on Diagnosing Dx, we’re joined by Kim Langone, SVP of R&D at Fellow Health, and former 10th employee at Genomic Health, where for 19 years, she played a pivotal role in developing Oncotype DX, a landmark diagnostic test for breast cancer.   With 24 years of experience in molecular diagnostics, Kimshares what it takes to build breakthrough science in a startup, scale it, and navigate...

This week on Diagnosing Dx, we’re joined by Heinz Steneberg, President and CEO of MDSS, for a deep dive into the role of Regulatory Strategy in Diagnostics and MedTech startups. From early-stage planning to FDA engagement, we cover the decisions that make or break go-to-market timelines - and how emerging models are shaping the regulatory future. 🔥 What You’ll Learn: • How to use FDA pre-submissi...